Drugs in India
Representational image | Photo: Pixabay
Text Size:

The National Pharmaceutical Pricing Authority last week raised the ceiling price of 21 essential drugs by 50 per cent to offset the rise in cost of ingredients imported from China. The present policy, Drug Price Control Order of 2013, has neither been very successful nor it is free of unintended consequences. Instead of existing price control mechanisms, the Indian government needs to find better remedies for sustainable production of drugs.

The price ceiling policy has been in place for more than two decades and India has one of the lowest drug prices in the world. But the out-of-pocket expenditure on healthcare remains high (61 per cent) and many Indians continue to be deprived of access to life-saving drugs. In terms of their relative per capita income, Indian consumers pay more than people in high-income countries. Hence, accessibility and affordability still remain critical challenges in India’s healthcare system.


Also read: Capping profits will wipe out low-cost generic medicines, drugmakers write to PM Modi


The unintended consequences

In India, prices of essential drugs are regulated by the central government under the Essential Commodities Act, 1955. The rationale behind price ceilings is to make drugs cheaper and easily accessible to everyone. This is important because a large section of the Indian population finds it difficult to bear the cost of medications, which forms a significant chunk of out-of-pocket expenditure on healthcare.

The National Pharmaceutical Pricing Authority (NPPA) was set up in 1997 to fix or revise prices of pharmaceutical products, enforce the provisions of DPCO (Drug Price Control Order) and monitor the prices of controlled and decontrolled drugs. Currently, DPCO lists 851 drug formulations whose prices can be capped. This policy is applicable for a specified dosage. The ceiling price is the average price for all brands selling a particular drug with more than 1 per cent of market share. If the price of a drug is below the ceiling price, it can be raised only after a year. This policy is, however, not applicable for patented drugs or fixed-dose combination (FDC) drugs.

The current drug price control policy has had many unintended consequences. For example, many pharmaceutical companies have opted to go out of production because their profit margins decreased. This has led to substandard and spurious drug manufacturers dominating the pharma market. In the absence of strict quality regulations, there has been a trade-off between price and quality; a report by the United States Trade Representative claims that 20 per cent of drugs in India are fake. Decrease in profit margins of quality manufacturers has led to a reduction in spending in research and development. It has deterred future investments in the pharmaceutical sector.

Many manufacturers migrated to non-essential drugs (80 per cent of the drugs in non-essential list) or stopped promoting essential drugs. For instance, an anti-fungal cream called Tolnaftate has not been promoted for several years now. Thus, the sale fell for drugs with capped prices, and rose for drugs that didn’t have a price ceiling. Moreover, there has not been much impact on the prices of many life-saving drugs (for example, HIV, cancer, non-communicable diseases) since they have not been on the list.

We are deeply grateful to our readers & viewers for their time, trust and subscriptions.

Quality journalism is expensive and needs readers to pay for it. Your support will define our work and ThePrint’s future.

SUBSCRIBE NOW

Some pharmaceutical companies in India have started promoting different drug categories: non-National List of Essential Medicines (NLEM), FDCs (not on NLEM) and non-standard dosages (for instance, doctors routinely prescribe splitting of medicines). An information asymmetry between the buyer and the seller has created a breeding ground for mis-selling and misinformation (adding or changing of ingredients) in India’s pharma industry.


Also read: Indians pay 70% less than the global median to buy medicines, study finds


Not price ceiling, need for other mechanisms

As prices of costlier drugs decrease, there is a tendency for a poor consumer to opt for a recognisable brand. The company selling drugs at a lower price loses the incentive to sell it at that price. Also, the chances of frivolous patents (as patented drugs are not on the essential list) have increased. The policy has also forced manufacturers to import Active Pharmaceutical Ingredients (API) and bulk drugs from China to reduce their input costs. So, it has damaged India’s indigenous drug manufacturing industries. About two-thirds of APIs are imported from China. Any threat from China has the potential to impact the manufacturing of critical drugs in India.


Also read: To fight China monopoly, Modi govt to speed up approvals for 4 mega bulk drugs parks


Instead of price controls, other mechanisms like promoting competition among manufacturers, strictly regulating the quality of drugs, bulk procurement of generic drugs by public institutions for distribution (Tamil Nadu being a good example), increase in public spending on healthcare, and tackling information asymmetry by promoting transparency will deliver better outcomes for India’s pharmaceutical industry .

The author is a public policy professional and a consultant at the Takshashila Institution. Views are personal. 

Subscribe to our channels on YouTube & Telegram

News media is in a crisis & only you can fix it

You are reading this because you value good, intelligent and objective journalism. We thank you for your time and your trust.

You also know that the news media is facing an unprecedented crisis. It is likely that you are also hearing of the brutal layoffs and pay-cuts hitting the industry. There are many reasons why the media’s economics is broken. But a big one is that good people are not yet paying enough for good journalism.

We have a newsroom filled with talented young reporters. We also have the country’s most robust editing and fact-checking team, finest news photographers and video professionals. We are building India’s most ambitious and energetic news platform. And we aren’t even three yet.

At ThePrint, we invest in quality journalists. We pay them fairly and on time even in this difficult period. As you may have noticed, we do not flinch from spending whatever it takes to make sure our reporters reach where the story is. Our stellar coronavirus coverage is a good example. You can check some of it here.

This comes with a sizable cost. For us to continue bringing quality journalism, we need readers like you to pay for it. Because the advertising market is broken too.

If you think we deserve your support, do join us in this endeavour to strengthen fair, free, courageous, and questioning journalism, please click on the link below. Your support will define our journalism, and ThePrint’s future. It will take just a few seconds of your time.

Support Our Journalism

Share Your Views

LEAVE A REPLY

Please enter your comment!
Please enter your name here